Literature DB >> 3334848

Characterization of the fluorescence of the antitumor agent, mitoxantrone.

D H Bell1.   

Abstract

Studies have been conducted on the absorption, fluorescence excitation and fluorescence emission of mitoxantrone, an important antineoplastic agent. Mitoxantrone has been found to fluoresce with excitation maxima at 610 and 660 nm and emission maximum at 685 nm. Further characterizations of the fluorescence were undertaken to study its usefulness in biological studies. Mitoxantrone fluorescence intensity is altered by pH and the emission spectrum is red-shifted by DNA. Furthermore, the fluorescence polarization is enhanced by DNA, confirming the binding of the antitumor agent to DNA. The fluorescence spectra are slightly modified by changes in ionic strength and the addition of albumin. Data establishing the usefulness of fluorescence to measure serum concentrations in the range of 0.0 to 100 nM are presented. Such determinations can distinguish serum mitoxantrone from its non-fluorescent primary metabolite.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3334848     DOI: 10.1016/0167-4781(88)90063-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.

Authors:  Irene Miranda-Lorenzo; Jorge Dorado; Enza Lonardo; Sonia Alcala; Alicia G Serrano; Jenifer Clausell-Tormos; Michele Cioffi; Diego Megias; Sladjana Zagorac; Anamaria Balic; Manuel Hidalgo; Mert Erkan; Joerg Kleeff; Aldo Scarpa; Bruno Sainz; Christopher Heeschen
Journal:  Nat Methods       Date:  2014-09-28       Impact factor: 28.547

Review 2.  Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.

Authors:  Miles A Miller; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2016-06-04       Impact factor: 15.470

3.  Systematic Identification of MCU Modulators by Orthogonal Interspecies Chemical Screening.

Authors:  Daniela M Arduino; Jennifer Wettmarshausen; Horia Vais; Paloma Navas-Navarro; Yiming Cheng; Anja Leimpek; Zhongming Ma; Alba Delrio-Lorenzo; Andrea Giordano; Cecilia Garcia-Perez; Guillaume Médard; Bernhard Kuster; Javier García-Sancho; Dejana Mokranjac; J Kevin Foskett; M Teresa Alonso; Fabiana Perocchi
Journal:  Mol Cell       Date:  2017-08-17       Impact factor: 17.970

4.  ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy.

Authors:  Xiaoding Xu; Phei Er Saw; Wei Tao; Yujing Li; Xiaoyuan Ji; Sushant Bhasin; Yanlan Liu; Dana Ayyash; Jonathan Rasmussen; Marc Huo; Jinjun Shi; Omid C Farokhzad
Journal:  Adv Mater       Date:  2017-07-06       Impact factor: 30.849

5.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

Authors:  Hazem Ghebeh; Cynthia Lehe; Eman Barhoush; Khaldoon Al-Romaih; Asma Tulbah; Monther Al-Alwan; Siti-Faujiah Hendrayani; Pulicat Manogaran; Ayodele Alaiya; Taher Al-Tweigeri; Abdelilah Aboussekhra; Said Dermime
Journal:  Breast Cancer Res       Date:  2010-07-13       Impact factor: 6.466

6.  Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

Authors:  Fei Shen; Barbara J Bailey; Shaoyou Chu; Aimee K Bence; Xinjian Xue; Priscilla Erickson; Ahmad R Safa; William T Beck; Leonard C Erickson
Journal:  J Pharmacol Exp Ther       Date:  2009-05-07       Impact factor: 4.030

7.  Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.

Authors:  M E Fox; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal.

Authors:  Prateek Kumar; Taniya Bhardwaj; Rajanish Giri
Journal:  RSC Adv       Date:  2022-02-16       Impact factor: 3.361

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.